Drug Trial Radar · NCT00075803
Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)
Last checked: Nov 19, 2026Latest source record: Jan 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
600
Actual
Start
Nov 2003
Primary completion
Sep 2006
Study completion Sep 2007
Sponsor
- Lead sponsor
- Medical College of WisconsinAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI); National Marrow Donor Program
- First posted
- Jan 13, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed as a Phase III, randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic transplant recipients. Recipients will be stratified by center and donor type (sibling vs. unrelated) and will be randomized to either the fluconazole or voriconazole arm in a 1:1 ratio.
Conditions
- Lymphoma
- Infection
- Leukemia
Interventions
FluconazoleDrug
Fluconazole will be administered orally once daily. Fluconazole capsules should be taken at least one hour before or one hour after a meal. If oral drug is not possible, it will be given intravenously once daily in a total volume of 200 mL in patients \> 12 years. For adults, each 200 mL infusion will be administered over 2 hours. In patients \< 12 years, intravenous doses will be prepared.
VoriconazoleDrug
Voriconazole will be administered orally twice daily. Voriconazole capsules should be taken at least one hour before or one hour after a meal. Taken concomitantly with food, bioavailability of voriconazole is reduced. If oral drug is not possible, it will be given intravenously at a dosage of 200 mg every 12 hours over two hours in patients \> 12 years. Each voriconazole dose will be diluted to a total volume of 200 mL in patients \> 12 years. Volumes of the formulation required to provide 4 mg/kg doses for children age \< 12 years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Fungal-free Survival (Percentage of Participants Alive and Free From Proven, Probable, or Presumptive Invasive Fungal Infection) at 180 Days Post-transplantTime frame: 180 days
Locations
33 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
UCSD Medical Center
La Jolla, California
Stanford Hospital and Clinics
Stanford, California
Children's National Medical Center
Washington D.C., District of Columbia
University of Florida College of Medicine (Shands)
Gainesville, Florida
H. Lee Moffitt Cancer Center
Tampa, Florida
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Indiana University Medical Center
Indianapolis, Indiana
Johns Hopkins/SKCCC
Baltimore, Maryland
Dana Farber Cancer Institute/Brigham & Womens
Boston, Massachusetts
Dana Farber Cancer Institute/Children's Hospital of Boston
Boston, Massachusetts
University of Michigan Medical Center
Ann Arbor, Michigan
Karmanos Cancer Institute/BMT
Detroit, Michigan
University of Minnesota
Minneapolis, Minnesota
Children's Mercy Hospitals and Clinics
Kansas City, Missouri
Kansas City Cancer Centers
Kansas City, Missouri
Cardinal Glennon Children's Hospital
St Louis, Missouri
Washington University/Barnes Jewish Hospital
St Louis, Missouri
Washington University/St. Louis Children's Hospital
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
Hackensack University Medical Center
Hackensack, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Duke University Medical Center
Durham, North Carolina
Wake Forest University Health Sciences
Winston-Salem, North Carolina
University Hospitals of Cleveland/Case Western
Cleveland, Ohio
Oregon Health Sciences University
Portland, Oregon
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania
University of Texas/MD Anderson CRC
Houston, Texas
Texas Transplant Institute
San Antonio, Texas
Utah BMT/Univ of Utah Med School
Salt Lake City, Utah
Fred Hutchinson Cancer Research Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.